AGC Biologics investing millions to add capabilities at Longmont plant

LONGMONT — As part of a $30 million investment in improvements at its Longmont manufacturing facility, AGC Biologics Inc. is adding viral vector suspension technology and gene-therapy production capabilities at the site. 

The Longmont plant, which AGC bought in 2021 as part of a major push into the Boulder County market soon after buying a similar facility in Boulder, has traditionally had adherent viral vector capabilities and the ability to manufacture cell therapies. 

The added capabilities, expected to come online around the third quarter of this year,  diversify the Longmont plant’s offering and “provide an in-depth variety of end-to-end cell and…